Reply to Dr Kawada: Late-Gestation Selective Serotonin Reuptake Inhibitor Exposure and Perinatal Mortality

Luke E. Grzeskowiak, Janna L. Morrison

Research output: Contribution to journalLetter

Abstract

We appreciate the interest by Dr Kawada1 in our study investigating neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors (SSRIs)2 and the call for additional analyses to examine clinical manifestations of the infants, in particular, fatal outcomes. Given the rarity of fatal outcomes, such as stillbirth (3.69 per 1000) and neonatal death (2.20 per 1000) as reported by Stephansson et al,3 our associated sample size was not sufficient to enable adequate statistical power to justify their investigation. We do, however, appreciate the significance of including data on infant mortality to more completely describe the effects of prenatal SSRI exposure on extreme clinical manifestations and the infant life prognosis. In accordance with this, we have included data on stillbirths and neonatal death later.
Original languageEnglish
Pages (from-to)751-752
Number of pages2
JournalJOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume34
Issue number6
DOIs
Publication statusPublished - Dec 2014
Externally publishedYes

Keywords

  • Letter
  • Letter to the editor
  • selective serotonin reuptake inhibitors
  • SSRIs
  • neonatal outcomes
  • late-gestation exposure
  • Perinatal Mortality

Fingerprint Dive into the research topics of 'Reply to Dr Kawada: Late-Gestation Selective Serotonin Reuptake Inhibitor Exposure and Perinatal Mortality'. Together they form a unique fingerprint.

  • Cite this